logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

Intellia Therapeutics: Reinforcing the Promise of Potentially Curing Diseases

Intellia Therapeutics in the News Intellia Therapeutics ( NTLA ) presented the first demonstration of physiological protein levels of human alpha-1 antitrypsin ( AAT ) in non-human primates (NHPs) following a single administration.  Intellia Therapeutics Liver Gene Insertion Technology Intellia’s...

Read More

December 15, 2020

0

From Inovio: Thermo Fisher Scientific Will Manufacture the Inovio COVID-19 Vaccine Candidate

Inovio COVID-19 Vaccine Candidate Will be Manufactured by Thermo Fisher Scientific Thermo Fisher Scientific ( TMO ) joins other contract development and manufacturing organizations in Inovio's global manufacturing consortium enabling Inovio ( INO ) to potentially scale INO-4800. With its...

Read More

September 9, 2020

0

Agenus Stock Rallied Yesterday

Why Agenus Stock Rallied Yesterday On September 2, 2020 we posted an article about Agenus ( AGEN ) under Trick or Trade titled, “ Agenus: Could It Be a Resurrection? "   The article was about the data Agenus announced from...

Read More

September 11, 2020

0

Eli Lilly Neutralizing Antibody LY-CoV555 Promises a Reduction in the Rate of COVID-19 Hospitalizations  

Eli Lilly and AbCellera Collaboration Result LY-C0V555  A lot of discoveries, followed by thorough experimentation beyond the vaccines, are taking place in the biotechnology and large biopharmaceutical companies to defeat COVID-19 . The most recently discovered product by AbCellera, which...

Read More

September 16, 2020

0

Rhythm Pharmaceuticals: Successful Results from Phase 3 Trial with Setmelanotide for Obesity Caused by Genetic BBS

Rhythm Pharmaceuticals Announces Successful Phase 3 Trial Results for Obesity In November 2020, when the U.S. FDA granted approval to the Rhythm Pharmaceuticals ( RYTM ) product IMCIVREE™ (setmelanotide) for obesity due to proopiomelanocortin ( POMC ), proprotein convertase subtilisin/Kexin...

Read More

December 29, 2020

0

Amgen's KRAS G12C Inhibitor Product Sotorasib Has Thrilling Results

Amgen and the KRAS G12C Protein Discovery The  RAS  gene family has been a subject for four decades of research. The family contains some of the most frequently mutated oncogenes in human cancers. Targeting the KRAS protein, the most commonly...

Read More

September 25, 2020

0

Revolution Medicines Inc Has Revolutionary News

Revolution Medicines Inc Revolution Medicines ( RVMD ) is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company possesses capabilities including deep chemical biology and cancer pharmacology know-how and novel...

Read More

September 25, 2020

0

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

bluebird bio Decision to Separate its Businesses bluebird bio ( BLUE )  will retain focus on its severe genetic disease ( SGD ) and will launch its oncology business ( Oncology Newco ) as a new entity. The Board of Directors...

Read More

January 14, 2021

0

Compugen: Why the Great Expectations from this Firm

The Compugen Story For those who are still asking about the value of Compugen’s ( CGEN ) discoveries our answer is that the best story written about this firm is its own autobiography.   We believe Compugen's accomplishments are extremely...

Read More

January 22, 2021

0

Johnson & Johnson Launches a Large Scale Phase 3 Trial of Its COVID-19 Vaccine. See Also: Intellia to Prove the Advantages of CRISPR Gene-Editing

Johnson & Johnson ENSEMBLE Trial for Its COVID-19 Vaccine Candidate Johnson & Johnson ( JNJ ) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial, ENSEMBLE, for its COVID-19 vaccine candidate, JNJ-78436735. The initiation of the ENSEMBLE trial...

Read More

September 29, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 12
  • 13
  • 14
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy